|
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
|
26 Jan, 2021 |
|
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients
|
21 Jan, 2021 |
|
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
|
12 Jan, 2021 |
|
AzurRx BioPharma CEO Issues Letter to Shareholders
|
08 Jan, 2021 |
|
AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference
|
07 Jan, 2021 |
|
AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
|
06 Jan, 2021 |
|
AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event
|
05 Jan, 2021 |
|
AzurRx BioPharma Announces $8.0 Million Offerings
|
04 Jan, 2021 |
|
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections
|
04 Jan, 2021 |
